


**Diagnostic, Correlative & Epidemiologic**

**UCI 08-70**  
Establishment of a Multidisciplinary Pancreatic Tumor Biorepository and Integrated Clinical Database (Jutric)

**Adjuvant Treatment**

**RTOG 0848**  
A Phase III Trial Evaluating Both Erlotinib and Chemoradiation as Adjuvant Treatment for Patients w/ Resected Head of Pancreas Adenocarcinoma (Zell)

**ALLIANCE A021501**  
Preoperative extended chemotherapy vs. chemotherapy plus hypo fractionated radiation therapy for borderline resectable adenocarcinoma of the head of the pancreas (Zell)



**Adenocarcinoma  
Stage IV Metastatic**

**1<sup>st</sup> LINE**

**ECOG EAY131 (MATCH)**  
Molecular Analysis for Therapy Choice (Bota)

**SWOG S1609**  
DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors (Bota)

**\*\*UCI 17-103**  
A Randomized, Open-label Phase 2 Study of Irinotecan liposomal injection (lip-IRI)-containing Regimens versus nab-paclitaxel plus Gemcitabine in Patients with Previously, Untreated, Metastatic Pancreatic Adenocarcinoma (Dayyani)

**UCI 15-94**  
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of PEGylated Recombinant Human Hyaluronidase (PEGPH20) in Combination With nab-Paclitaxel Plus Gemcitabine Compared With Placebo Plus nab-Paclitaxel and Gemcitabine in Subjects with Hyaluronan-High Stage IV Previously Untreated Pancreatic Ductal Adenocarcinoma (Zell)

**Cholangiocarcinoma**

**UCI 17-49\*\***  
A Phase 1b, Randomized, Open-Label Study of PEGylated Recombinant Human Hyaluronidase (PEGPH20) in Combination with Cisplatin Plus Gemcitabine and PEGPH20 in Combination with Atezolizumab and Cisplatin Plus Gemcitabine Compared with Cisplatin Plus Gemcitabine in Hyaluronan-High (HA-high) Subjects with Previously Untreated, Unresectable, Locally Advanced, or Metastatic Intrahepatic and Extrahepatic Cholangiocarcinoma and Gallbladder Adenocarcinoma (Dayyani)

**UCI 17-39**  
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-controlled Study of AG-120 in Previously-treated Subjects with Nonresectable or Metastatic Cholangiocarcinoma with an IDH Mutation (Dayyani)

**UCI 16-64**  
A Phase 2, Open-Label, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects with Advanced/Metastatic or Surgically Unresectable Cholangiocarcinoma Including FGFR2 Translocations Who Failed Previous Therapy (Imagawa)